Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
Rhea-AI Summary
Denali Therapeutics (Nasdaq: DNLI) will host a live webcast on Thursday, February 5, 2026 at 12:30 p.m. Pacific Time to review presentations on its Enzyme TransportVehicle™ (ETV) programs delivered at the 22nd Annual WORLDSymposium, held February 2–6, 2026 in San Diego.
The webcast will highlight the ETV approach to enable enzyme replacement therapy delivery across the whole body, including the brain, and is accessible via the Events page of Denali’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – DNLI
On the day this news was published, DNLI gained 4.60%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.0% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $163M to the company's valuation, bringing the market cap to $3.70B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: BLTE +1.42%, FOLD +0.14%, while IDYA -2.31%, TVTX -1.52%, AGIO -0.07%. With no peers in the momentum scanner and DNLI up 0.69%, trading appeared more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | 2026 milestones update | Positive | +7.4% | Outlined 2026 priorities, clinical readouts, and highlighted strong cash and financings. |
| Dec 30 | Clinical data NEJM | Positive | -1.0% | Published positive Phase 1/2 tividenofusp alfa data supporting FDA priority review. |
| Dec 10 | Public equity offering | Negative | -10.6% | Priced stock and pre-funded warrant offering targeting about $200M gross proceeds. |
| Dec 09 | Proposed equity offering | Negative | -0.1% | Announced proposed $200M stock and warrant sale with additional $30M option. |
| Dec 04 | Royalty funding deal | Positive | +6.8% | Entered $275M royalty funding agreement tied to future tividenofusp alfa sales. |
Positive strategic and partnership news (milestones, funding) tended to align with price gains, while financing-related offerings aligned with share price pressure. One notable divergence occurred when strong clinical data coincided with a modest negative move.
Over the last few months, Denali reported several significant milestones. A Dec 4, 2025 royalty funding agreement for tividenofusp alfa and a Jan 6, 2026 update on 2026 priorities and anticipated milestones both aligned with gains above 6%. In contrast, December underwritten offerings around $200 million aligned with double-digit and modest declines. Strong Phase 1/2 data for tividenofusp alfa published in NEJM on Dec 30, 2025 diverged from a slightly negative price reaction. Today’s webcast announcement fits into this pattern of ongoing program visibility and investor communication.
Market Pulse Summary
This announcement highlights a webcast focused on Denali’s Enzyme TransportVehicle™ programs at the 22nd Annual WORLDSymposium™, adding visibility to its platform rather than introducing new data. The stock traded at $21.74, about 10.7% below its 52-week high and above the $15.61 200-day MA, reflecting prior momentum from milestones, funding, and regulatory progress. Investors may watch future clinical readouts, regulatory decisions, and any additional financing steps as more material catalysts beyond this communication event.
Key Terms
enzyme transportvehicle medical
enzyme replacement therapies medical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live webcast to review presentations on its Enzyme TransportVehicle™ (ETV) programs at the upcoming 22nd Annual WORLDSymposium™ being held February 2-6, 2026, in San Diego, California. These presentations will demonstrate the broad potential of the ETV to enable the delivery of enzyme replacement therapies to the whole body, including the brain. Titles and times for the presentations were previously announced in a corporate news release here. The live webcast will begin at 12:30 p.m. Pacific Time on Thursday, February 5, 2026, and can be accessed on the Events page of the Investor section on Denali’s corporate website at https://investors.denalitherapeutics.com/events or click here.
About Denali Therapeutics
Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform. With a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform the lives of people living with neurodegenerative, lysosomal storage and other serious diseases. For more information, please visit www.denalitherapeutics.com.
Investor Contact:
Laura Hansen, Ph.D.
hansen@dnli.com
Media Contact:
Erin Patton
epatton@dnli.com
FAQ
When is Denali Therapeutics (DNLI) hosting the ETV webcast for WORLDSymposium 2026?
How can investors access the DNLI webcast of ETV presentations on February 5, 2026?
What topics will DNLI cover in the Enzyme TransportVehicle presentations at WORLDSymposium 2026?
Which event are Denali’s ETV presentations associated with during February 2026?
Will the DNLI webcast review previously announced presentation titles and times from WORLDSymposium?
